Clinical Trial

Autologous Tolerogenic Dendritic Cells (ATDC) for Highly Sensitized Kidney Transplant Recipients

Name: Autologous Tolerogenic Dendritic Cells (ATDC) for Highly Sensitized Kidney Transplant Recipients — clinical trial record (NCT06852625)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ATDC-PICI

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The ATDC-PICI study is a Phase Ib, single-arm, prospective, non-randomized, multicentric trial, to evaluate the safety of ATDC cell product as adjunctive therapy to standard of care (SOC) in highly sensitized kidney transplant recipients.

Trial Details

NCT Number	NCT06852625
Lead Sponsor	Fundacion Clinic per a la Recerca Biomédica
Conditions	Kidney Transplant Rejection
Enrollment	30 participants
Start Date	2025-05
Primary Completion	2028-03 (estimated)
Study Completion	2028-03 (estimated)
Updated on ClinicalTrials.gov	2025-02-28